Clinical Trials in Los Angeles

Showing 3781-3800 of 16,901 trials

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

NCT06848231

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.

Multiple System Atrophy

Yoda Therapeutics Inc.75 participantsStarted Mar 2025

Los Angeles, California, United States • Boston, Massachusetts, United States • Rochester, Minnesota, United States +6 more locations

RECRUITINGPhase 3< 1 mile

Abatacept in Immune Checkpoint Inhibitor Myocarditis

NCT05335928

The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.

Myocarditis AcuteCancer

Massachusetts General Hospital390 participantsStarted Jul 2022

Los Angeles, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +28 more locations

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

Abatacept in Immune Checkpoint Inhibitor Myocarditis

Find Trials by Condition in Los Angeles

Phase 2a Study of the Safety, Tolerability, and Pharmacokinetics of Topically Administered PRN473 (SAR444727) in Patients With Mild to Moderate Atopic Dermatitis

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

A Study of LM-24C5 For Advanced Solid Tumors

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning